Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study details the successful use of metyrapone to manage severe Cushing’s disease symptoms and stabilize a patient’s biochemical parameters before she underwent pituitary surgery.

This study suggests that combining LMWHA solution and HCO might improve mild to moderate urinary incontinence in women with GSM, potentially offering benefits over HA therapy alone, but further research is needed.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study developed a physician-guided algorithm to manage cutaneous adverse events from hormonal therapy in cancer patients, aiming to reduce treatment interruptions and enhance quality of life.

This study found that most UK women prescribed cyproterone acetate/ethinylestradiol before and after 2013 had conditions aligning with approved indications and prior acne treatment.

This update provides information on new drug approvals but does not offer new clinical research findings.

Topical tretinoin 0.025% cream is an effective treatment for Eruptive Vellus Hair Cysts in children.

This study found that US adults with classic congenital adrenal hyperplasia most preferred a hypothetical adjunctive therapy that prevents glucocorticoid-induced weight gain over other potential benefits.

The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.

This study found that while the new cytopurine/pentadecanoic glyceride topical solution significantly improved total hair and daily shed hair counts in AGA patients, it did not show significant differences compared to placebo in other measures.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This case report highlights a rare instance of esophageal carcinoma in a patient with Cronkhite-Canada syndrome, emphasizing the importance of endoscopic surveillance for malignant gastrointestinal tumors in these patients.

This case report describes a 60-year-old woman with Cronkhite-Canada syndrome whose symptoms and polyposis improved following prednisolone therapy, but emphasizes the need for periodic digestive tract screening due to associated cancer risks.

This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

This study found no significant difference in anagen rate improvement between the CYP-based dietary supplement and placebo in women over 60 with telogen effluvium, possibly due to variable patient inclusion related to hair growth seasonality.

This review discusses the development and potential therapeutic applications of steroid sulfatase inhibitors for hormone-dependent disorders and cognitive dysfunction, reporting no new clinical results.

In this study, three cases of Cronkhite-Canada syndrome revealed small bowel mucosal lesions, but these findings did not correlate with clinical symptoms or steroid treatment outcomes.

This systematic review found that treatments for sickle cell disease-related priapism are clinically diverse, with etilefrine, pseudoephedrine/etilefrine-5 inhibitors, and finasteride appearing promising, but further research with robust study designs is needed to establish evidence-based practices.

This study found that men prescribed Finasteride had a lower incidence of bladder cancer compared to those not on the medication, but this protective effect was observed only in Caucasians and Hispanics.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

This study describes the diagnosis and successful management of Cronkhite-Canada syndrome in a 78-year-old man, highlighting improvement in symptoms and endoscopic findings after treatment with prednisone and supportive therapies.

In this article, the authors reported that calcipotriol/betamethasone dipropionate aerosol foam significantly improved scalp psoriasis symptoms in three patients by reducing itching and improving flaky patches within a four-week treatment period, confirming its efficacy and enhanced skin penetration compared to older formulations.